Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22190202 | 0.82 | FNTA (0.33) | ALDH1A1TP53L3MBTL1 | |
| SCHEMBL27357275 | 0.82 | FNTA (0.33) | ALDH1A1TP53L3MBTL1 | |
| SCHEMBL20683584 | 0.80 | CA2 (0.35) | CA2 | |
| SCHEMBL1385033 | 0.79 | — | — | |
| SCHEMBL19540738 | 0.78 | CA12 (0.39) | CA2ALDH1A1TP53L3MBTL1 | |
| SCHEMBL13220253 | 0.75 | PPARA (0.31) | CA2 | |
| SCHEMBL13241230 | 0.75 | TAS1R3 (0.40) | CA2ALDH1A1 | |
| SCHEMBL20846989 | 0.73 | CA2 (0.33) | CA2 | |
| SCHEMBL5197727 | 0.72 | — | — | |
| SCHEMBL11706114 | 0.69 | ALDH1A1 (0.35) | ALDH1A1TP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190106414-A1 | SUBSTITUTED-INDOLE-COMPOUNDS AS ESTROGEN RECEPTOR DOWN-REGULATORS | Luoxin Healthcare Science and Technology Development (Beijing) Ltd. (CN) | 2019-04-11 | — | — | US | disclosed |
| EP-3434668-A1 | INDOLO-SUBSTITUTED-PIPERIDINE COMPOUNDS AS ESTROGEN RECEPTOR DEGRADING AGENT | Luoxin Biotechnology (Shanghai) Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8318723-B2 | Pyrazine compounds, their use and methods of preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318723-B2 | Pyrazine compounds, their use and methods of preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| EP-2061762-B1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-20100210627-A1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210627-A1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1995240-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008022164-A2 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | CA2 1044/4885ALDH1A1 1934/4885TP53 2980/4885 |
| US-20190106414-A1 | SUBSTITUTED-INDOLE-COMPOUNDS AS ESTROGEN RECEPTOR DOWN-REGULATORS | ESR2, ESR1, GPER1 | CA2 4561/4885ALDH1A1 1922/4885TP53 349/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | CA2 595/4885ALDH1A1 2376/4885TP53 3598/4885 |
| US-20100210627-A1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | CDK2, PIM1, CCNK | CA2 2565/4885ALDH1A1 3122/4885TP53 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.